coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

被引：8
|
作者：
Paolo A Ascierto
Grant A. McArthur
Brigitte Dréno
James Larkin
Gabriella Liszkay
Michele Maio
Mario Mandala
Lev Demidov
Daniil Stroyakovskiy
Luc Thomas
Luis de la Cruz-Merino
Victoria Atkinson
Caroline Dutriaux
Claus Garbe
Ilsung Chang
Stephen P. Hack
Antoni Ribas
机构：
[1] Istituto Nazionale Tumori Fondazione G. Pascale,
[2] Peter MacCallum Cancer Centre,undefined
[3] Hôtel Dieu Place Alexis Ricordeau,undefined
[4] The Royal Marsden Hospital,undefined
[5] National Institute of Oncology,undefined
[6] Azienda Ospedaliera Universitaria Senese,undefined
[7] Papa Giovanni XXIII Hospital,undefined
[8] N.N. Blokhin Russian Cancer Research Center,undefined
[9] Moscow City Oncology Hospital 62,undefined
[10] Centre Hospitalier Lyon Sud,undefined
[11] Hospital Universitario Virgen Macarena,undefined
[12] Princess Alexandra Hospital,undefined
[13] Hopital Saint André,undefined
[14] University of Tübingen,undefined
[15] Genentech,undefined
[16] Inc,undefined
[17] Jonsson Comprehensive Cancer Center at the University of California,undefined
[18] Los Angeles,undefined
来源：
Journal of Translational Medicine | / 13卷 / Suppl 1期
关键词：
Overall Survival; Metastatic Melanoma; Vemurafenib; Creatine Phosphokinase; BRAF Inhibitor;
D O I：
10.1186/1479-5876-13-S1-O4
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
    Gutzmer, Ralf
    Stroyakovskiy, Daniil
    Gogas, Helen
    Robert, Caroline
    Lewis, Karl
    Protsenko, Svetlana
    Pereira, Rodrigo P.
    Eigentler, Thomas
    Rutkowski, Piotr
    Demidov, Lev
    Manikhas, Georgy Moiseevich
    Yan, Yibing
    Huang, Kuan-Chieh
    Uyei, Anne
    McNally, Virginia
    McArthur, Grant A.
    Ascierto, Paolo A.
    LANCET, 2020, 395 (10240): : 1835 - 1844
  • [2] BUDGET IMPACT MODEL OF COBIMETINIB IN COMBINATION WITH VEMURAFENIB FOR PREVIOUSLY UNTREATED BRAF V600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
    Kyriopoulos, D.
    Athanasakis, K.
    Akratos, A.
    Theodoropoulou, F.
    Caporis, X.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2017, 20 (09) : A423 - A423
  • [3] A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
    Lopez-Martin, Jose A.
    Berrocal, Alfonso
    Gonzalez-Cao, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    Maio, Michele
    Lewis, Karl
    Demidov, Lev
    Mandala, Mario
    Bondarenko, Igor
    Ascierto, Paolo A.
    Herbert, Christopher
    Mackiewicz, Andrzej
    Rutkowski, Piotr
    Guminski, Alexander
    Goodman, Grant R.
    Simmons, Brian
    Ye, Chenglin
    Yan, Yibing
    Schadendorf, Dirk
    LANCET ONCOLOGY, 2018, 19 (04): : 510 - 520
  • [5] Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
    Brigitte Dréno
    Paolo A Ascierto
    Victoria Atkinson
    Gabriella Liszkay
    Michele Maio
    Mario Mandalà
    Lev Demidov
    Daniil Stroyakovskiy
    Luc Thomas
    Luis de la Cruz-Merino
    Caroline Dutriaux
    Claus Garbe
    Karen Bartley
    Thomas Karagiannis
    Ilsung Chang
    Isabelle Rooney
    Daniel O Koralek
    James Larkin
    Grant A McArthur
    Antoni Ribas
    British Journal of Cancer, 2018, 118 : 777 - 784
  • [6] Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
    Lu Si
    Xiaoshi Zhang
    Zhen Xu
    Qiudi Jiang
    Lilian Bu
    Xuan Wang
    Lili Mao
    Weijiang Zhang
    Nicole Richie
    Jun Guo
    BMC Cancer, 18
  • [7] 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
    Ascierto, Paolo A.
    Dreno, Brigitte
    Larkin, James
    Ribas, Antoni
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Atkinson, Victoria
    Dutriaux, Caroline
    Garbe, Claus
    Hsu, Jessie
    Jones, Surai
    Li, Haocheng
    McKenna, Edward
    Voulgari, Athina
    McArthur, Grant A.
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5225 - 5235
  • [8] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
    Ascierto, Paolo A.
    McArthur, Grant A.
    Dreno, Brigitte
    Atkinson, Victoria
    Liszkay, Gabrielle
    Di Giacomo, Anna Maria
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Yan, Yibing
    Wongchenko, Matthew
    Chang, Ilsung
    Hsu, Jessie J.
    Koralek, Daniel O.
    Rooney, Isabelle
    Ribas, Antoni
    Larkin, James
    LANCET ONCOLOGY, 2016, 17 (09): : 1248 - 1260
  • [9] Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma
    Dreno, Brigitte
    Ascierto, Paolo A.
    Atkinson, Victoria
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Bartley, Karen
    Karagiannis, Thomas
    Chang, Ilsung
    Rooney, Isabelle
    Koralek, Daniel O.
    Larkin, James
    McArthur, Grant A.
    Ribas, Antoni
    BRITISH JOURNAL OF CANCER, 2018, 118 (06) : 777 - 784
  • [10] Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial (vol 395, pg 1835, 2020)
    Gutzmer, R.
    Stroyakovskiy, D.
    Gogas, H.
    Robert, Caroline
    Lewis, Karl
    Protsenko, Svetlana
    Pereira, Rodrigo P.
    Eigentler, Thomas
    Rutkowski, Piotr
    Demidov, Lev
    Manikhas, Georgy Moiseevich
    Yan, Yibing
    Huang, Kuan-Chieh
    Uyei, Anne
    McNally, Virginia
    McArthur, Grant A.
    Ascierto, Paolo A.
    LANCET, 2020, 396 (10249): : 466 - 466
12345